CY1114930T1 - Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της - Google Patents

Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της

Info

Publication number
CY1114930T1
CY1114930T1 CY20131101156T CY131101156T CY1114930T1 CY 1114930 T1 CY1114930 T1 CY 1114930T1 CY 20131101156 T CY20131101156 T CY 20131101156T CY 131101156 T CY131101156 T CY 131101156T CY 1114930 T1 CY1114930 T1 CY 1114930T1
Authority
CY
Cyprus
Prior art keywords
gastrolite
ingredients
composition containing
containing cancer
organic matter
Prior art date
Application number
CY20131101156T
Other languages
Greek (el)
English (en)
Inventor
Yossi Ben
Amir Sagi
Original Assignee
Ben Gurion University Of The Negev Research And Development Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University Of The Negev Research And Development Authority filed Critical Ben Gurion University Of The Negev Research And Development Authority
Publication of CY1114930T1 publication Critical patent/CY1114930T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
CY20131101156T 2006-10-05 2013-12-20 Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της CY1114930T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
EP07827185.5A EP2068891B1 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use

Publications (1)

Publication Number Publication Date
CY1114930T1 true CY1114930T1 (el) 2016-12-14

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101156T CY1114930T1 (el) 2006-10-05 2013-12-20 Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της

Country Status (14)

Country Link
US (2) US20100098774A1 (cg-RX-API-DMAC7.html)
EP (1) EP2068891B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010505818A (cg-RX-API-DMAC7.html)
CN (1) CN101563091A (cg-RX-API-DMAC7.html)
AU (1) AU2007303786B2 (cg-RX-API-DMAC7.html)
CA (1) CA2665141C (cg-RX-API-DMAC7.html)
CY (1) CY1114930T1 (cg-RX-API-DMAC7.html)
DK (1) DK2068891T3 (cg-RX-API-DMAC7.html)
ES (1) ES2439741T3 (cg-RX-API-DMAC7.html)
IL (1) IL178495A (cg-RX-API-DMAC7.html)
PL (1) PL2068891T3 (cg-RX-API-DMAC7.html)
PT (1) PT2068891E (cg-RX-API-DMAC7.html)
SI (1) SI2068891T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008041236A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
US8802160B2 (en) 2007-10-22 2014-08-12 Amorphical Ltd. Stable amorphous calcium carbonate comprising phosphorylated amino acids
JP2015500333A (ja) * 2011-12-13 2015-01-05 アモーフィカル リミテッド. カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム
EP2882687B1 (en) 2012-08-07 2018-10-10 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
US20150374747A1 (en) * 2013-02-11 2015-12-31 Amorphical Ltd. Amorphous calcium carbonate for accelerated bone growth
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
CA2956048C (en) 2014-07-31 2023-01-24 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
AU2016273058B2 (en) * 2015-06-04 2021-05-20 Amorphical Ltd. Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
CN108471796A (zh) * 2015-12-14 2018-08-31 雀巢产品技术援助有限公司 用于促进脑的髓鞘形成的营养组合物和婴儿配方食品
EP4233907A3 (en) * 2015-12-14 2024-01-10 Société des Produits Nestlé S.A. Nutritional compositions and infant formulas to promote myelination in the brain
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
KR102828392B1 (ko) 2016-01-18 2025-07-02 아모피컬 리미티드 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
US12629390B2 (en) 2016-01-18 2026-05-19 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
IL266149B (en) * 2016-10-25 2022-08-01 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
MX2022000947A (es) 2019-07-23 2022-04-26 Amorphical Ltd Carbonato de calcio amorfo para mejorar el rendimiento deportivo.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
ES2295391T3 (es) * 2001-08-16 2008-04-16 Cmp Therapeutics Limited Microparticulas de quitina y sus usos medicos.
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
AU2003271016A1 (en) * 2003-09-17 2005-04-06 Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
ES2447747T3 (es) * 2004-05-26 2014-03-12 Ben Gurion University Of The Negev Research And Development Authority Composiciones administrables por vía oral que comprenden carbonato cálcico amorfo estable
AU2005296271A1 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Also Published As

Publication number Publication date
SI2068891T1 (sl) 2014-02-28
CA2665141A1 (en) 2008-04-10
CN101563091A (zh) 2009-10-21
PT2068891E (pt) 2013-12-27
EP2068891A2 (en) 2009-06-17
DK2068891T3 (da) 2014-01-13
AU2007303786A1 (en) 2008-04-10
JP2010505818A (ja) 2010-02-25
IL178495A (en) 2014-12-31
ES2439741T3 (es) 2014-01-24
EP2068891B1 (en) 2013-09-25
WO2008041236A3 (en) 2009-05-14
US20130122117A1 (en) 2013-05-16
IL178495A0 (en) 2007-02-11
CA2665141C (en) 2015-03-24
WO2008041236A2 (en) 2008-04-10
US8728533B2 (en) 2014-05-20
PL2068891T3 (pl) 2014-03-31
US20100098774A1 (en) 2010-04-22
AU2007303786B2 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
CR11299A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
CR9672A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
EA200800614A1 (ru) Новое применение пептидных соединений для лечения мышечной боли
EA200901170A1 (ru) Органические соединения и их применение
PT2068891E (pt) Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilização
EA200800100A1 (ru) Соединения азаиндазола и способы применения
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
CY1113975T1 (el) Παραγοντες για προληψη και θεραπεια διαταραχων που περιλαμβανουν διαφοροποιηση των υποδοχεων ryr
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
BG108491A (en) 5-ht receptor ligands and uses thereof
ATE499940T1 (de) Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
CY1114952T1 (el) Ενεργοποιητες θειενο[2,3-b]πυριδινοδιονης της αμρκ και θεραπευτικες χρησεις αυτων
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
ATE476418T1 (de) Benzamidderivate und assoziierte verwendungen
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων